SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Actinium Pharmaceuticals, Inc. – ‘10-Q’ for 3/31/20 – ‘EX-101.INS’

On:  Monday, 6/29/20, at 6:27pm ET   ·   For:  3/31/20   ·   Accession #:  1213900-20-16168   ·   File #:  1-36374   ·   Correction:  This Filing’s Metadata was Corrected ® and Changed as of 6/29/20 by the SEC on 7/7/20.

Previous ‘10-Q’:  ‘10-Q’ on 11/12/19 for 9/30/19   ·   Next:  ‘10-Q’ on 8/14/20 for 6/30/20   ·   Latest:  ‘10-Q’ on 4/26/24 for 3/31/24   ·   1 Reference:  By:  Actinium Pharmaceuticals, Inc. – ‘S-3’ on 8/7/20

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/29/20  Actinium Pharmaceuticals, Inc.    10-Q®       3/31/20   40:2.1M                                   Edgar Agents LLC/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    366K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     18K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     18K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     14K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     14K 
12: R1          Document and Entity Information                     HTML     47K 
13: R2          Consolidated Balance Sheets (Unaudited)             HTML     85K 
14: R3          Consolidated Balance Sheets (Unaudited)             HTML     36K 
                (Parenthetical)                                                  
15: R4          Consolidated Statements of Operations (Unaudited)   HTML     44K 
16: R5          Consolidated Statement of Changes in Stockholders'  HTML     46K 
                Equity (Unaudited)                                               
17: R6          Consolidated Statements of Cash Flows (Unaudited)   HTML     71K 
18: R7          Description of Business and Summary of Significant  HTML     48K 
                Accounting Policies                                              
19: R8          Commitments and Contingencies                       HTML     23K 
20: R9          Leases                                              HTML     39K 
21: R10         Equity                                              HTML     41K 
22: R11         Description of Business and Summary of Significant  HTML     79K 
                Accounting Policies (Policies)                                   
23: R12         Description of Business and Summary of Significant  HTML     24K 
                Accounting Policies (Tables)                                     
24: R13         Leases (Tables)                                     HTML     38K 
25: R14         Equity (Tables)                                     HTML     31K 
26: R15         Description of Business and Summary of Significant  HTML     27K 
                Accounting Policies (Details)                                    
27: R16         Description of Business and Summary of Significant  HTML     22K 
                Accounting Policies (Details 1)                                  
28: R17         Description of Business and Summary of Significant  HTML     15K 
                Accounting Policies (Details Textual)                            
29: R18         Commitments and Contingencies (Details 1)           HTML     32K 
30: R19         Leases (Details)                                    HTML     26K 
31: R20         Leases (Details 1)                                  HTML     29K 
32: R21         Leases (Details 2)                                  HTML     19K 
33: R22         Leases (Details 3)                                  HTML     18K 
34: R23         Leases (Details 4)                                  HTML     29K 
35: R24         Leases (Details Textual)                            HTML     15K 
36: R25         Equity (Details)                                    HTML     67K 
37: R26         Equity (Details Textual)                            HTML     72K 
39: XML         IDEA XML File -- Filing Summary                      XML     65K 
38: EXCEL       IDEA Workbook of Financial Reports                  XLSX     40K 
 6: EX-101.INS  XBRL Instance -- atnm-20200331                       XML    406K 
 8: EX-101.CAL  XBRL Calculations -- atnm-20200331_cal               XML     92K 
 9: EX-101.DEF  XBRL Definitions -- atnm-20200331_def                XML    216K 
10: EX-101.LAB  XBRL Labels -- atnm-20200331_lab                     XML    539K 
11: EX-101.PRE  XBRL Presentations -- atnm-20200331_pre              XML    372K 
 7: EX-101.SCH  XBRL Schema -- atnm-20200331                         XSD     99K 
40: ZIP         XBRL Zipped Folder -- 0001213900-20-016168-xbrl      Zip     64K

‘EX-101.INS’   —   XBRL Instance — atnm-20200331

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.3a -->
<!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
<!-- Field: Doc-Info; Name: Source; Value: atnm%2D20200331.xfr; Date: 2020%2D06%2D26T20:49:02Z -->
<!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:atnm="http://actiniumpharmaceuticals.com/20200331">
<link:schemaRef xlink:href="atnm-20200331.xsd" xlink:type="simple"/>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2018-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2012-06-01to2012-06-15_custom_LicenseAndSponsoredResearchAgreementMember_custom_FredHutchinsonCancerResearchCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:AgreementAxis"> atnm:LicenseAndSponsoredResearchAgreementMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> atnm:FredHutchinsonCancerResearchCenterMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2012-06-01 </xbrli:startDate>
<xbrli:endDate> 2012-06-15 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2018-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2018-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember173911536">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2018-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2019-01-01to2019-03-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2019-01-01 </xbrli:startDate>
<xbrli:endDate> 2019-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2019-01-01to2019-03-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2019-01-01 </xbrli:startDate>
<xbrli:endDate> 2019-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2019-01-01 </xbrli:startDate>
<xbrli:endDate> 2019-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2019-01-01 </xbrli:startDate>
<xbrli:endDate> 2019-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-03-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2018-10-03to2018-10-31_custom_LincolnParkCapitalFundLlcMember_custom_PurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> atnm:LincolnParkCapitalFundLlcMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="atnm:AgreementAxis"> atnm:PurchaseAgreementMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2018-10-03 </xbrli:startDate>
<xbrli:endDate> 2018-10-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_OptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:OptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2019-01-01to2019-03-31_us-gaap_OptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:OptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2019-01-01 </xbrli:startDate>
<xbrli:endDate> 2019-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2019-01-01to2019-03-31_us-gaap_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2019-01-01 </xbrli:startDate>
<xbrli:endDate> 2019-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_custom_OakRidgeNationalLaboratoryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> atnm:OakRidgeNationalLaboratoryMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_CapitalLeaseObligationsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis"> us-gaap:CapitalLeaseObligationsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2019-01-01to2019-03-31_us-gaap_CapitalLeaseObligationsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis"> us-gaap:CapitalLeaseObligationsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2019-01-01 </xbrli:startDate>
<xbrli:endDate> 2019-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_custom_OperatingLeaseLiabilitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:LeaseAxis"> atnm:OperatingLeaseLiabilitiesMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_custom_FinanceLeaseLiabilitiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="atnm:LeaseAxis"> atnm:FinanceLeaseLiabilitiesMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> us-gaap:StockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_WarrantMember545104671">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_us-gaap_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_us-gaap_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> us-gaap:StockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31_us-gaap_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> us-gaap:StockOptionMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31_us-gaap_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_custom_LincolnParkCapitalFundLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> atnm:LincolnParkCapitalFundLlcMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2019-01-01to2019-03-31_custom_SeriesAWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> atnm:SeriesAWarrantsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2019-01-01 </xbrli:startDate>
<xbrli:endDate> 2019-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-04-04to2020-04-24_us-gaap_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-04-04 </xbrli:startDate>
<xbrli:endDate> 2020-04-24 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2019-11-04to2019-11-30_custom_OakRidgeNationalLaboratoryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> atnm:OakRidgeNationalLaboratoryMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2019-11-04 </xbrli:startDate>
<xbrli:endDate> 2019-11-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-01-31_custom_MedpaceIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> atnm:MedpaceIncMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-01-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-04-04to2020-04-30_us-gaap_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-04-04 </xbrli:startDate>
<xbrli:endDate> 2020-04-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-06-15to2020-06-30_us-gaap_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-06-15 </xbrli:startDate>
<xbrli:endDate> 2020-06-30 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-06-01to2020-06-19_srt_ScenarioForecastMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:StatementScenarioAxis"> srt:ScenarioForecastMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-06-01 </xbrli:startDate>
<xbrli:endDate> 2020-06-19 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-06-19_us-gaap_CommonStockMember_srt_ScenarioForecastMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementScenarioAxis"> srt:ScenarioForecastMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-06-19 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-06-19_us-gaap_WarrantMember_srt_ScenarioForecastMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementScenarioAxis"> srt:ScenarioForecastMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-06-19 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-06-29">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001388320 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-06-29 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:unit id="shares">
<xbrli:measure> xbrli:shares </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="USD">
<xbrli:measure> iso4217:USD </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="USD_per_Share">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure> iso4217:USD </xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure> xbrli:shares </xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<xbrli:unit id="pure">
<xbrli:measure> xbrli:pure </xbrli:measure>
</xbrli:unit>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31" unitRef="shares" decimals="INF"> 97202 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-03-31" unitRef="shares" decimals="INF"> 51257 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31_us-gaap_OptionMember" unitRef="shares" decimals="INF"> 11061 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-03-31_us-gaap_OptionMember" unitRef="shares" decimals="INF"> 7784 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-03-31_us-gaap_WarrantMember" unitRef="shares" decimals="INF"> 86141 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-03-31_us-gaap_WarrantMember" unitRef="shares" decimals="INF"> 43473 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<dei:EntityRegistrantName contextRef="From2020-01-01to2020-03-31"> Actinium Pharmaceuticals, Inc. </dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31"> 0001388320 </dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31"> false </dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31"> --12-31 </dei:CurrentFiscalYearEndDate>
<dei:DocumentType contextRef="From2020-01-01to2020-03-31"> 10-Q </dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="From2020-01-01to2020-03-31"> 2020-03-31 </dei:DocumentPeriodEndDate>
<dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31"> Q1 </dei:DocumentFiscalPeriodFocus>
<dei:EntityFilerCategory contextRef="From2020-01-01to2020-03-31"> Non-accelerated Filer </dei:EntityFilerCategory>
<dei:EntitySmallBusiness contextRef="From2020-01-01to2020-03-31"> true </dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany contextRef="From2020-01-01to2020-03-31"> false </dei:EntityEmergingGrowthCompany>
<dei:EntityCurrentReportingStatus contextRef="From2020-01-01to2020-03-31"> Yes </dei:EntityCurrentReportingStatus>
<dei:EntityShellCompany contextRef="From2020-01-01to2020-03-31"> false </dei:EntityShellCompany>
<dei:EntityFileNumber contextRef="From2020-01-01to2020-03-31"> 001-36374 </dei:EntityFileNumber>
<dei:EntityIncorporationStateCountryCode contextRef="From2020-01-01to2020-03-31"> DE </dei:EntityIncorporationStateCountryCode>
<dei:EntityInteractiveDataCurrent contextRef="From2020-01-01to2020-03-31"> Yes </dei:EntityInteractiveDataCurrent>
<dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31"> 2020 </dei:DocumentFiscalYearFocus>
<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-03-31"> P2Y4M24D </us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-03-31"> P2Y6M0D </us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="-3"> 8813000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3"> 195554000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3"> -186857000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember173911536" unitRef="USD" decimals="-3"> 116000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3"> 119000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3"> 197751000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3"> -192527000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" unitRef="USD" decimals="-3"> 5343000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 3020000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 5644000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3"> 165000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3"> 175000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3"> 214237000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3"> 217273000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3"> -208758000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3"> -214428000 </us-gaap:StockholdersEquity>
<us-gaap:Revenues contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:Revenues contextRef="From2019-01-01to2019-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 4151000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 4336000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 1532000 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 1363000 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 5683000 </us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 5699000 </us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> -5683000 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> -5699000 </us-gaap:OperatingIncomeLoss>
<us-gaap:InterestIncomeExpenseNet contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 13000 </us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 29000 </us-gaap:InterestIncomeExpenseNet>
<us-gaap:NonoperatingIncomeExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 13000 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 29000 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-01-01to2020-03-31" unitRef="USD_per_Share" decimals="INF"> -0.03 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-01-01to2019-03-31" unitRef="USD_per_Share" decimals="INF"> -0.05 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-01-01to2020-03-31" unitRef="shares" decimals="INF"> 173001307 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-01-01to2019-03-31" unitRef="shares" decimals="INF"> 117197086 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember173911536" unitRef="shares" decimals="INF"> 115703044 </us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF"> 119136036 </us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF"> 164701167 </us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF"> 174839536 </us-gaap:SharesOutstanding>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 372000 </us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 316000 </us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3"> 316000 </us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3"> 372000 </us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF"> 2221 </us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
<us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> -5670000 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> -5670000 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3"> -5670000 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3"> -5670000 </us-gaap:ProfitLoss>
<atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 1504000 </atnm:StockIssuedDuringPeriodValueWarrantsExercised>
<atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3"> 2000 </atnm:StockIssuedDuringPeriodValueWarrantsExercised>
<atnm:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3"> 1502000 </atnm:StockIssuedDuringPeriodValueWarrantsExercised>
<atnm:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF"> 2506271 </atnm:StockIssuedDuringPeriodSharesWarrantsExercised>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation - Unaudited Interim Financial Information -</b> The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the "SEC") with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's annual report on Form 10-K for the year ended December 31, 2019.</p>
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:LessorLeasesPolicyTextBlock contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>– The Company has operating and finance leases for corporate office space, office equipment and furniture located at the corporate office space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line basis over the lease term.</p>
</us-gaap:LessorLeasesPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Fair Value of Financial Instruments</b> - Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p>
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p>
</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -</b> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p>
</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2020-01-01to2020-03-31">
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; width: 76%">Options</td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 9%">11,061</td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 9%">7,784</td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">86,141</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,473</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">97,202</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">51,257</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<atnm:LeaseInitialTerm contextRef="From2020-01-01to2020-03-31"> P1Y </atnm:LeaseInitialTerm>
<us-gaap:LeaseCostTableTextBlock contextRef="From2020-01-01to2020-03-31">
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b>(in thousands)</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">93</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">93</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">26</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>
</us-gaap:LeaseCostTableTextBlock>
<atnm:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock contextRef="From2020-01-01to2020-03-31">
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Cash flow information:</b></font></td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three months ended</b></font></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31,<br /> 2020</b></font></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31,<br /> 2019</b></font></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities:</font></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-indent: -9pt; width: 76%"><font style="font: 10pt Times New Roman, Times, Serif">Operating cash flow use from operating leases</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; width: 9%"><font style="font: 10pt Times New Roman, Times, Serif">94</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; width: 9%"><font style="font: 10pt Times New Roman, Times, Serif">86</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font: 10pt Times New Roman, Times, Serif">Operating cash flow use from finance leases</font></td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4</font></td> <td> </td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font: 10pt Times New Roman, Times, Serif">Financing cash flow use from finance leases</font></td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">19</font></td> <td> </td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">18</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt; text-indent: -9pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-cash activity:</b></font></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt; text-indent: -9pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font: 10pt Times New Roman, Times, Serif">Right-of-use assets obtained in exchange for lease obligations:</font></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font: 10pt Times New Roman, Times, Serif">Operating leases</font></td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">83</font></td> <td> </td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,177</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font: 10pt Times New Roman, Times, Serif">Finance Leases</font></td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td> </td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">302</font></td> <td> </td></tr> </table>
</atnm:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock>
<atnm:ScheduleOrDescriptionOfWeightedAverageTerm contextRef="From2020-01-01to2020-03-31">
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average remaining lease term:</td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating leases</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2.4 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance Leases</td><td> </td> <td style="text-align: right">2.5 years</td></tr> </table>
</atnm:ScheduleOrDescriptionOfWeightedAverageTerm>
<atnm:ScheduleOfWeightedAverageDiscountRate contextRef="From2020-01-01to2020-03-31">
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>Weighted average discount rates:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance Leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td></tr> </table>
</atnm:ScheduleOfWeightedAverageDiscountRate>
<atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2020-01-01to2020-03-31">
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left; font-weight: bold">(in thousands)</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold">Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 76%">2020 (excluding three months ended March 31, 2020)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">281</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">71</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">252</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">20230</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">910</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">233</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(85</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">825</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">211</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>
</atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock>
<us-gaap:OperatingLeaseCost contextRef="From2020-01-01to2020-03-31_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3"> 25000 </us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost contextRef="From2019-01-01to2019-03-31_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3"> 26000 </us-gaap:OperatingLeaseCost>
<us-gaap:FinanceLeaseInterestExpense contextRef="From2020-01-01to2020-03-31_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3"> 5000 </us-gaap:FinanceLeaseInterestExpense>
<us-gaap:FinanceLeaseInterestExpense contextRef="From2019-01-01to2019-03-31_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3"> 6000 </us-gaap:FinanceLeaseInterestExpense>
<us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="From2020-01-01to2020-03-31_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3"> 20000 </us-gaap:FinanceLeaseRightOfUseAssetAmortization>
<us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="From2019-01-01to2019-03-31_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3"> 20000 </us-gaap:FinanceLeaseRightOfUseAssetAmortization>
<us-gaap:OperatingLeaseExpense contextRef="From2020-01-01to2020-03-31_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3"> 93000 </us-gaap:OperatingLeaseExpense>
<us-gaap:OperatingLeaseExpense contextRef="From2019-01-01to2019-03-31_us-gaap_CapitalLeaseObligationsMember" unitRef="USD" decimals="-3"> 93000 </us-gaap:OperatingLeaseExpense>
<us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 302000 </us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 83000 </us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 1177000 </us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:FinanceLeasePrincipalPayments contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 19000 </us-gaap:FinanceLeasePrincipalPayments>
<us-gaap:FinanceLeasePrincipalPayments contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 18000 </us-gaap:FinanceLeasePrincipalPayments>
<us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 4000 </us-gaap:FinanceLeaseInterestPaymentOnLiability>
<us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 6000 </us-gaap:FinanceLeaseInterestPaymentOnLiability>
<us-gaap:OperatingLeasePayments contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 94000 </us-gaap:OperatingLeasePayments>
<us-gaap:OperatingLeasePayments contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 86000 </us-gaap:OperatingLeasePayments>
<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2020-03-31" unitRef="pure" decimals="INF"> 0.08 </us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
<us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2020-03-31" unitRef="pure" decimals="INF"> 0.08 </us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
<atnm:MaturitiesOfLeaseLiabilities contextRef="AsOf2020-03-31_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" decimals="-3"> 825000 </atnm:MaturitiesOfLeaseLiabilities>
<atnm:MaturitiesOfLeaseLiabilities contextRef="AsOf2020-03-31_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3"> 211000 </atnm:MaturitiesOfLeaseLiabilities>
<atnm:PaymentWithImputedInterestPremium contextRef="AsOf2020-03-31_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" decimals="-3"> 85000 </atnm:PaymentWithImputedInterestPremium>
<atnm:PaymentWithImputedInterestPremium contextRef="AsOf2020-03-31_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3"> 22000 </atnm:PaymentWithImputedInterestPremium>
<atnm:LeaseLiabilityPaymentsDue contextRef="AsOf2020-03-31_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" decimals="-3"> 910000 </atnm:LeaseLiabilityPaymentsDue>
<atnm:LeaseLiabilityPaymentsDue contextRef="AsOf2020-03-31_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3"> 233000 </atnm:LeaseLiabilityPaymentsDue>
<atnm:MaturitiesLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2020-03-31_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" xsi:nil="true"/>
<atnm:MaturitiesLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2020-03-31_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3"> 4000 </atnm:MaturitiesLeaseLiabilityPaymentsDueYearFour>
<atnm:MaturitiesLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-03-31_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" decimals="-3"> 252000 </atnm:MaturitiesLeaseLiabilityPaymentsDueYearThree>
<atnm:MaturitiesLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-03-31_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3"> 64000 </atnm:MaturitiesLeaseLiabilityPaymentsDueYearThree>
<atnm:MaturitiesLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-03-31_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" decimals="-3"> 377000 </atnm:MaturitiesLeaseLiabilityPaymentsDueYearTwo>
<atnm:MaturitiesLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-03-31_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3"> 94000 </atnm:MaturitiesLeaseLiabilityPaymentsDueYearTwo>
<atnm:MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-03-31_custom_OperatingLeaseLiabilitiesMember" unitRef="USD" decimals="-3"> 281000 </atnm:MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths>
<atnm:MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-03-31_custom_FinanceLeaseLiabilitiesMember" unitRef="USD" decimals="-3"> 71000 </atnm:MaturitiesLeaseLiabilityPaymentsDueNextTwelveMonths>
<us-gaap:OtherRestrictedAssetsCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 391000 </us-gaap:OtherRestrictedAssetsCurrent>
<us-gaap:OtherRestrictedAssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 391000 </us-gaap:OtherRestrictedAssetsCurrent>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 9300000 </us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 900000 </us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2020-01-01to2020-03-31_custom_LincolnParkCapitalFundLlcMember" unitRef="USD" decimals="-3"> 200000 </us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2019-01-01to2019-03-31_custom_SeriesAWarrantsMember" unitRef="USD" decimals="-3"> 1500000 </us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2020-01-01to2020-03-31_custom_LincolnParkCapitalFundLlcMember" unitRef="shares" decimals="INF"> 800000 </us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 2500000 </us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 400000 </us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<atnm:ShareCancelledDueToTerminationOfEmployees contextRef="From2020-01-01to2020-03-31" unitRef="shares" decimals="INF"> 300 </atnm:ShareCancelledDueToTerminationOfEmployees>
<us-gaap:StockOptionPlanExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 400000 </us-gaap:StockOptionPlanExpense>
<us-gaap:StockOptionPlanExpense contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 300000 </us-gaap:StockOptionPlanExpense>
<atnm:WarrantsExercisedByWarrantHolders contextRef="From2019-01-01to2019-03-31_custom_SeriesAWarrantsMember" unitRef="shares" decimals="INF"> 2500 </atnm:WarrantsExercisedByWarrantHolders>
<atnm:WarrantsExercisedByWarrantHolders contextRef="From2020-06-01to2020-06-19_srt_ScenarioForecastMember" unitRef="shares" decimals="INF"> 0.0001 </atnm:WarrantsExercisedByWarrantHolders>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 1700000 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:SubsequentEventDescription contextRef="From2020-04-04to2020-04-24_us-gaap_SubsequentEventMember"> The Company issued and sold 128.3 million shares of common stock and 82.5 million pre-funded warrants to purchase shares of common stock. The price to the public in this offering for each share of common stock was $0.15 and for each pre-funded warrant was $0.1499. Each pre-funded warrant has an exercise price of $0.0001 per share and is exercisable immediately upon issuance. The warrants are subject to certain limitations on beneficial ownership. Gross proceeds from this offering to Actinium were $31.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Net proceeds from this offering were $29.1 million. </us-gaap:SubsequentEventDescription>
<us-gaap:SubsequentEventDescription contextRef="From2020-04-04to2020-04-30_us-gaap_SubsequentEventMember"> The Company sold 171 thousand common shares through its at-the-market program and realized net proceeds of $35 thousand. </us-gaap:SubsequentEventDescription>
<us-gaap:SubsequentEventDescription contextRef="From2020-06-15to2020-06-30_us-gaap_SubsequentEventMember"> The Company issued 157 thousand restricted common shares for consulting services. </us-gaap:SubsequentEventDescription>
<atnm:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="From2012-06-01to2012-06-15_custom_LicenseAndSponsoredResearchAgreementMember_custom_FredHutchinsonCancerResearchCenterMember"> Royalty payments of 2% of net sales will be due to FHCRC. </atnm:DescriptionOfRoyaltyPaymentToRelatedParty>
<us-gaap:ResearchAndDevelopmentInProcess contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 1500000 </us-gaap:ResearchAndDevelopmentInProcess>
<us-gaap:ResearchAndDevelopmentInProcess contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 400000 </us-gaap:ResearchAndDevelopmentInProcess>
<atnm:PurchaseOfMaterials contextRef="From2020-01-01to2020-03-31_custom_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="-3"> 100000 </atnm:PurchaseOfMaterials>
<atnm:PurchaseOfMaterials contextRef="From2019-11-04to2019-11-30_custom_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="-3"> 300000 </atnm:PurchaseOfMaterials>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 5942000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 9254000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 48000 </us-gaap:RestrictedCashCurrent>
<us-gaap:RestrictedCashCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 48000 </us-gaap:RestrictedCashCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 816000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 786000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 6806000 </us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 10088000 </us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 101000 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 113000 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 815000 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 807000 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:FinanceLeaseRightOfUseAsset contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 201000 </us-gaap:FinanceLeaseRightOfUseAsset>
<us-gaap:FinanceLeaseRightOfUseAsset contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 221000 </us-gaap:FinanceLeaseRightOfUseAsset>
<us-gaap:SecurityDeposit contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 50000 </us-gaap:SecurityDeposit>
<us-gaap:SecurityDeposit contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 50000 </us-gaap:SecurityDeposit>
<us-gaap:RestrictedCash contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 391000 </us-gaap:RestrictedCash>
<us-gaap:RestrictedCash contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 391000 </us-gaap:RestrictedCash>
<us-gaap:Assets contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 8364000 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 11670000 </us-gaap:Assets>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 4041000 </us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 4598000 </us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:NotesPayableCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 268000 </us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 381000 </us-gaap:NotesPayableCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 321000 </us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 286000 </us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 80000 </us-gaap:FinanceLeaseLiabilityCurrent>
<us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 79000 </us-gaap:FinanceLeaseLiabilityCurrent>
<us-gaap:LiabilitiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 4710000 </us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 5344000 </us-gaap:LiabilitiesCurrent>
<atnm:LongtermOperatingLeaseObligationsNoncurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 504000 </atnm:LongtermOperatingLeaseObligationsNoncurrent>
<atnm:LongtermOperatingLeaseObligationsNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 531000 </atnm:LongtermOperatingLeaseObligationsNoncurrent>
<atnm:LongtermFinanceLeaseObligationsNoncurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 130000 </atnm:LongtermFinanceLeaseObligationsNoncurrent>
<atnm:LongtermFinanceLeaseObligationsNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 151000 </atnm:LongtermFinanceLeaseObligationsNoncurrent>
<us-gaap:Liabilities contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 5344000 </us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 6026000 </us-gaap:Liabilities>
<us-gaap:PreferredStockValue contextRef="AsOf2020-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 175000 </us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 165000 </us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 217273000 </us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 214237000 </us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> -214428000 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> -208758000 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 8364000 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 11670000 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 249000 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 237000 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-03-31" unitRef="USD_per_Share" decimals="INF"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USD_per_Share" decimals="INF"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-03-31" unitRef="shares" decimals="INF"> 50000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="shares" decimals="INF"> 50000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-03-31" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-03-31" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="shares" xsi:nil="true"/>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-03-31" unitRef="shares" decimals="INF"> 1000000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="shares" decimals="INF"> 1000000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-03-31" unitRef="USD_per_Share" decimals="INF"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USD_per_Share" decimals="INF"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2020-03-31" unitRef="shares" decimals="INF"> 174839536 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" unitRef="shares" decimals="INF"> 164701167 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-03-31" unitRef="shares" decimals="INF"> 174839536 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="shares" decimals="INF"> 164701167 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF"> 924500 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF"> 10138369 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-06-01to2020-06-19_srt_ScenarioForecastMember" unitRef="shares" decimals="INF"> 55700000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 2674000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 380000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3"> 1000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3"> 379000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3"> 10000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3"> 2664000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:InterestPaidNet contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 4000 </us-gaap:InterestPaidNet>
<us-gaap:InterestPaidNet contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 2000 </us-gaap:InterestPaidNet>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="-3"> 14104000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-03-31" unitRef="USD" decimals="-3"> 10356000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-03-31" unitRef="USD" decimals="-3"> 6381000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-12-31" unitRef="USD" decimals="-3"> 9693000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> -3312000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> -3748000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 2542000 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 1792000 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:ProceedsFromWarrantExercises contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromWarrantExercises contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 1504000 </us-gaap:ProceedsFromWarrantExercises>
<atnm:ProceedsFromIssuanceOfCommonStockAndWarrantNet contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 2674000 </atnm:ProceedsFromIssuanceOfCommonStockAndWarrantNet>
<atnm:ProceedsFromIssuanceOfCommonStockAndWarrantNet contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 380000 </atnm:ProceedsFromIssuanceOfCommonStockAndWarrantNet>
<us-gaap:RepaymentsOfNotesPayable contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 113000 </us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 74000 </us-gaap:RepaymentsOfNotesPayable>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> -51000 </us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 51000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> -5854000 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> -5489000 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<atnm:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> -76000 </atnm:IncreaseDecreaseInOperatingLeaseLiabilities>
<atnm:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> -63000 </atnm:IncreaseDecreaseInOperatingLeaseLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> -558000 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> -493000 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 30000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> -317000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:DepreciationAndAmortization contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 108000 </us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 104000 </us-gaap:DepreciationAndAmortization>
<us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> 372000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> 316000 </us-gaap:ShareBasedCompensation>
<us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="-3"> -5670000 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-03-31" unitRef="USD" decimals="-3"> -5670000 </us-gaap:NetIncomeLoss>
<us-gaap:CommitmentsAndContingencies contextRef="AsOf2020-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-03-31_us-gaap_StockOptionMember">
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Term <br /> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br /> Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, December 31, 2019</td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 9%">11,385</td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 9%">1.17</td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 9%">7.88</td><td style="text-align: left; width: 1%"> </td><td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 9%">          -</td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(324</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">0.55</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Outstanding, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11,061</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">1.19</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">7.77</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Exercisable, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,278</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">6.61</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-03-31_us-gaap_WarrantMember545104671">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Term <br /> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br /> Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">86,141</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.69</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.95</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">301</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Cancelled/Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">86,141</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.69</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.70</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">267</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">85,934</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.68</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.70</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">267</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:DevelopmentInProcess contextRef="AsOf2020-01-31_custom_MedpaceIncMember" unitRef="USD" decimals="-3"> 11900000 </us-gaap:DevelopmentInProcess>
<atnm:MilestonePayment contextRef="From2012-06-01to2012-06-15_custom_LicenseAndSponsoredResearchAgreementMember_custom_FredHutchinsonCancerResearchCenterMember" unitRef="USD" decimals="-3"> 1000000 </atnm:MilestonePayment>
<atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-03-31"> P3Y0M0D </atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
<atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-01-01to2019-03-31"> P3Y0M0D </atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-03-31_us-gaap_WarrantMember" unitRef="shares" decimals="INF"> 86141 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-03-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF"> 11061 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF"> 11385 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_us-gaap_WarrantMember" unitRef="shares" decimals="INF"> 86141 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-01to2020-03-31_us-gaap_StockOptionMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-01to2020-03-31_us-gaap_WarrantMember545104671" unitRef="shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-01to2020-03-31_us-gaap_WarrantMember545104671" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2020-01-01to2020-03-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF"> 324 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2020-01-01to2020-03-31_us-gaap_WarrantMember545104671" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-03-31_us-gaap_WarrantMember" unitRef="shares" decimals="INF"> 85934 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-03-31_us-gaap_StockOptionMember" unitRef="shares" decimals="INF"> 5278 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-03-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF"> 0.69 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-03-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF"> 1.19 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF"> 1.17 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF"> 0.69 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-03-31_us-gaap_WarrantMember545104671" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-03-31_us-gaap_WarrantMember545104671" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-03-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF"> 0.55 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-03-31_us-gaap_WarrantMember545104671" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-03-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF"> 0.68 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-03-31_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF"> 2.00 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-01to2020-03-31_us-gaap_StockOptionMember"> P7Y10M17D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-01to2020-03-31_us-gaap_WarrantMember545104671"> P2Y11M12D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2020-01-01to2020-03-31_us-gaap_StockOptionMember"> P7Y9M7D </atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
<atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2020-01-01to2020-03-31_us-gaap_WarrantMember545104671"> P2Y8M12D </atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-03-31_us-gaap_StockOptionMember"> P6Y7M10D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-03-31_us-gaap_WarrantMember545104671"> P2Y8M12D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-03-31_us-gaap_WarrantMember" unitRef="USD" decimals="-3"> 267000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-03-31_us-gaap_StockOptionMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2019-12-31_us-gaap_StockOptionMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2019-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="-3"> 301000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2020-03-31_us-gaap_WarrantMember" unitRef="USD" decimals="-3"> 267000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2020-03-31_us-gaap_StockOptionMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="From2019-01-01to2019-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Leases </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company adopted ASC 842 as of January 1, 2019, using a modified retrospective approach and applying the standard's transition provisions at January 1, 2019, the effective date. The Company made an accounting policy election to exclude from balance sheet reporting those leases with initial terms of 12 months or less.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized when the obligation is probable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate is not readily determinable in the Company's leases, the incremental borrowing rate is used based on the information available at commencement date in determining the present value of lease payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority of the Company's leases as the reasonably certain threshold is not met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At March 31, 2020, the Company has an operating lease for corporate office space and two finance leases for office equipment and furniture located in the corporate office space. In addition, the Company has auxiliary corporate office space that it rents on a month-to-month basis; this rental is accounted for as an operating lease with the same term as the Company's main office in the same building.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b>(in thousands)</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">93</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">93</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">26</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental cash flow information related to leases are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Cash flow information:</b></font></td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three months ended</b></font></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31,<br /> 2020</b></font></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31,<br /> 2019</b></font></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities:</font></td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; padding-left: 9pt; text-indent: -9pt"><font style="font: 10pt Times New Roman, Times, Serif">Operating cash flow use from operating leases</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">94</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">86</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font: 10pt Times New Roman, Times, Serif">Operating cash flow use from finance leases</font></td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4</font></td> <td> </td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font: 10pt Times New Roman, Times, Serif">Financing cash flow use from finance leases</font></td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">19</font></td> <td> </td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">18</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt; text-indent: -9pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-cash activity:</b></font></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt; text-indent: -9pt"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font: 10pt Times New Roman, Times, Serif">Right-of-use assets obtained in exchange for lease obligations:</font></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font: 10pt Times New Roman, Times, Serif">Operating leases</font></td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">83</font></td> <td> </td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,177</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-indent: -9pt"><font style="font: 10pt Times New Roman, Times, Serif">Finance Leases</font></td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td> </td> <td> </td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">302</font></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows at March 31, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average remaining lease term:</td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating leases</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2.4 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance Leases</td><td> </td> <td style="text-align: right">2.5 years</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the Company's leases do not provide an implicit rate, the Company used its incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments. Below is information on the weighted average discount rates used:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>Weighted average discount rates:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Finance Leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>   </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left; font-weight: bold">(in thousands)</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold">Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 76%">2020 (excluding three months ended March 31, 2020)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">281</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">71</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">252</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">20230</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">910</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">233</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(85</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">825</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">211</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>
</us-gaap:LesseeOperatingLeasesTextBlock>
<atnm:AggregateValueOfCommonStock contextRef="From2018-10-03to2018-10-31_custom_LincolnParkCapitalFundLlcMember_custom_PurchaseAgreementMember" unitRef="USD" decimals="-3"> 32500000 </atnm:AggregateValueOfCommonStock>
<atnm:DescriptionOfWarrants contextRef="From2020-06-15to2020-06-30_us-gaap_SubsequentEventMember"> Holders of 36.0 million pre-funded warrants exercised their warrants at $0.0001 per share and received 36.0 million common shares. </atnm:DescriptionOfWarrants>
<atnm:WarrantToPurchaseOfCommonStock contextRef="From2020-06-01to2020-06-19_srt_ScenarioForecastMember" unitRef="shares" decimals="INF"> 21300000 </atnm:WarrantToPurchaseOfCommonStock>
<us-gaap:SharePrice contextRef="AsOf2020-06-19_us-gaap_CommonStockMember_srt_ScenarioForecastMember" unitRef="USD_per_Share" decimals="INF"> 0.325 </us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="AsOf2020-06-19_us-gaap_WarrantMember_srt_ScenarioForecastMember" unitRef="USD_per_Share" decimals="INF"> 0.3249 </us-gaap:SharePrice>
<atnm:GrossProceedsFromWarrantExercises contextRef="From2020-06-01to2020-06-19_srt_ScenarioForecastMember" unitRef="USD" decimals="-3"> 25000000 </atnm:GrossProceedsFromWarrantExercises>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2020-06-01to2020-06-19_srt_ScenarioForecastMember" unitRef="USD" decimals="-3"> 22800000 </us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<atnm:PotentialReverseStockSplitPolicyTextBlock contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>NYSE American Notification and Potential Reverse Stock Split </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 29, 2020, the Company received a deficiency letter from the NYSE American LLC, or NYSE American, indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide because its shares of common stock have been selling for a substantial period of time at a low price per share. Pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the NYSE American staff determined that the Company’s continued listing is predicated on the Company effecting a reverse stock split of its common stock or otherwise demonstrating sustained price improvement within a reasonable period of time, which the staff determined to be no later than October 29, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company does not effectuate a reverse stock split to maintain compliance with NYSE American listing requirements, it could be delisted from the exchange. On October 18, 2019, the Company’s board of directors, or the Board, unanimously approved, subject to stockholder approval, an amendment to the Company’s certificate of incorporation to effect a reverse stock split of its outstanding common stock by combining outstanding shares of common stock into a lesser number of outstanding shares of common stock by a ratio of not more than 1-for-75 prior to December 18, 2020, with the exact ratio to be set within this range by the Board at its sole discretion. At its Annual Meeting of Stockholders held on December 18, 2019, the Company’s stockholders approved such amendment to its certificate of incorporation. Upon the effectiveness of the amendment to its certificate of incorporation effecting the reverse stock split, the outstanding shares of its common stock will be reclassified and combined into a lesser number of shares such that one share of common stock will be issued for a specified number of shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board has the sole discretion to effect the amendment and reverse stock split, and to fix the specific ratio for the reverse stock split, provided that the ratio would be not be more than 1-for-75. The reverse stock split would become effective upon the filing of an amendment to the Company’s certificate of incorporation with the Secretary of State of the State of Delaware, or at the later time set forth in the amendment. The exact timing of the amendment will be determined by the Board based on its evaluation as to when such action will be the most advantageous to the Company and its stockholders.</p>
</atnm:PotentialReverseStockSplitPolicyTextBlock>
<us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="From2020-01-01to2020-03-31">
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td style="text-align: justify"><b>(in thousands)</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,942</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,254</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Restricted cash – current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash – long-term</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">391</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">391</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,381</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,693</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>
</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and Summary of Significant Accounting Policies</b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business -</b> Actinium Pharmaceuticals, Inc. (the “Company”, “Actinium”, or “We”) is a clinical-stage, biopharmaceutical company applying its proprietary platform technology and deep understanding of radioimmunobiology to the development of novel targeted therapies known as ARCs or Antibody Radiation-Conjugates. Radiation is an effective therapeutic modality that is used in the treatment of over fifty percent of all cancer patients and often combined with chemotherapy and immunotherapy for greater therapeutic effect. Radiation is typically administered from outside the body, which constrains the amount that can be administered to patients due to dose-limiting toxicities. In addition, due to the diffuse nature of the external radiation beam, its usage is limited to solid tumors and cannot be used in blood cancers, which are diffuse. ARCs combine the cell-killing ability of a radioisotope payload with a targeting agent, such as a monoclonal antibody, or mAb, to deliver radiation inside the body to specific cells, to potentially generate greater efficacy and less toxicity. ARCs usage is broader than external delivered radiation as they can be used for both solid tumors and blood cancers. Blood or hematologic cancers are highly sensitive to radiation and our clinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologic cancers. Our clinical programs are focused on two primary areas: targeted conditioning prior to a cell or gene therapy procedure and therapeutics, either in combination with other agents or as a monotherapy. Our product development strategy is actively informed by clinical data with our ARCs in over 500 patients, including the ongoing SIERRA trial. Our clinical pipeline has emanated from our AWE, or Antibody Warhead Enabling technology platform, which is protected by over 110 issued and pending patents, trade secrets and know-how and is being utilized in a collaborative research partnership with Astellas Pharma, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation - Unaudited Interim Financial Information -</b> The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s annual report on Form 10-K for the year ended December 31, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation -</b> The consolidated financial statements include the Company’s accounts and those of the Company’s wholly owned subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates in Financial Statement Presentation</b> - The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Impact of COVID–19 Pandemic on Financial Statements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, a novel strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China to other countries has resulted in the World Health Organization (“WHO”) declaring the outbreak of COVID-19 as a “pandemic,” or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world have imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses, and many local jurisdictions continue to have such restrictions in place.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As local jurisdictions continue to put restrictions in place, the Company’s ability to continue to operate its business may also be limited. Such events may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could materially affect the Company’s business, financial condition and results of operations. In response to COVID-19, the Company implemented remote working and thus far, has not experienced a significant disruption or delay in its operations as it relates to the clinical development or drug production of our drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The spread of COVID-19, which has caused a broad impact globally, may materially affect the Company economically. While the ultimate economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic has resulted significant disruptions in the general commercial activity and the global economy and caused financial market volatility and uncertainty in significant and unforeseen ways in the recent months. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect the Company’s business and the value of the Company’s common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, COVID-19 may also result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with IRB’s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, COVID-19 has not had a financial impact on the Company. However, COVID-19 has caused severe disruptions in transportation and limited access to the Company’s facility, resulting in limited support from its staff and professional advisors. The small size of the Company’s accounting staff and the additional responsibilities emanating from COVID-19 have presented difficulties to the Company’s ability to complete this Report on Form 10-Q in a timely manner, resulting in its delay.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>NYSE American Notification and Potential Reverse Stock Split </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 29, 2020, the Company received a deficiency letter from the NYSE American LLC, or NYSE American, indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide because its shares of common stock have been selling for a substantial period of time at a low price per share. Pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the NYSE American staff determined that the Company’s continued listing is predicated on the Company effecting a reverse stock split of its common stock or otherwise demonstrating sustained price improvement within a reasonable period of time, which the staff determined to be no later than October 29, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company does not effectuate a reverse stock split to maintain compliance with NYSE American listing requirements, it could be delisted from the exchange. On October 18, 2019, the Company’s board of directors, or the Board, unanimously approved, subject to stockholder approval, an amendment to the Company’s certificate of incorporation to effect a reverse stock split of its outstanding common stock by combining outstanding shares of common stock into a lesser number of outstanding shares of common stock by a ratio of not more than 1-for-75 prior to December 18, 2020, with the exact ratio to be set within this range by the Board at its sole discretion. At its Annual Meeting of Stockholders held on December 18, 2019, the Company’s stockholders approved such amendment to its certificate of incorporation. Upon the effectiveness of the amendment to its certificate of incorporation effecting the reverse stock split, the outstanding shares of its common stock will be reclassified and combined into a lesser number of shares such that one share of common stock will be issued for a specified number of shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board has the sole discretion to effect the amendment and reverse stock split, and to fix the specific ratio for the reverse stock split, provided that the ratio would be not be more than 1-for-75. The reverse stock split would become effective upon the filing of an amendment to the Company’s certificate of incorporation with the Secretary of State of the State of Delaware, or at the later time set forth in the amendment. The exact timing of the amendment will be determined by the Board based on its evaluation as to when such action will be the most advantageous to the Company and its stockholders.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary of cash, cash equivalents and restricted cash at March 31, 2020 and December 31, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><b>(in thousands)</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,942</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,254</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Restricted cash – current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash – long-term</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">391</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">391</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,381</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,693</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Current restricted cash relates to credit card accounts, while long-term restricted cash relates to a certificate of deposit held as collateral for a letter of credit issued in connection with the Company’s lease for corporate office space.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>– The Company has operating and finance leases for corporate office space, office equipment and furniture located at the corporate office space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line basis over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Fair Value of Financial Instruments</b> - Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -</b> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share</b> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the reporting period. For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and warrants using the treasury stock method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three months ended March 31, 2020 and 2019, the Company’s potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11,061</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7,784</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">86,141</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,473</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">97,202</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">51,257</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Accounting Standards Recently Adopted </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, FASB issued ASU 2018-13, <i>Fair Value Measurement - Disclosure Framework (Topic 820).</i> The updated guidance improves the disclosure requirements on fair value measurements, primarily associated with Level 3 fair value measurements and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance of the standard for disclosures modified or removed with a delay of adoption of the additional disclosures until their effective date. The Company adopted this standard effective January 1, 2020 and the standard did not have a significant impact to the Company’s financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2018, FASB issued ASU 2018-18, C<i>ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, </i>which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company adopted this standard effective January 1, 2020 and the standard did not have a significant impact to the Company’s financial statements.</p>
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Commitments and Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Agreements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has entered into agreements with third parties for the rights to certain intellectual property, manufacturing and clinical trial services under which the Company may incur obligations to make payments including upfront payments as well as milestone and royalty payments. Notable inclusions in this category are: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; font-size: 10pt"> </td> <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td> <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Oak Ridge National Laboratory ("ORNL") – The Company is contracted to purchase radioactive material to be used for research and development, with a renewal option at the contract end. During the three months ended March 31, 2020 and 2019, the Company purchased material from ORNL of $0.1 million in each period. In November 2019, the Company signed a contract with ORNL to purchase $0.3 million of radioactive material during calendar year 2020.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center ("FHCRC") to build upon previous and ongoing clinical trials with BC8 (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial with BC8. The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC. A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug utilizing the licensed BC 8 antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC. </font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in"> </p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">c.</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 16, 2016, the Company entered into an agreement with Medpace, Inc. ("Medpace"), a contract research organization. Medpace provides project management services for the Iomab-B study. In January 2020, the Company and Medpace amended their agreement. The total project is currently estimated to cost $11.9 million. Medpace bills the Company when services are rendered and the Company records the related expense to research and development costs. During the three months ended March 31, 2020 and 2019, the Company paid Medpace $1.5 million and $0.4 million, respectively. These payments are for Medpace project management services and pass-through expenses incurred by investigators and clinical sites.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in"> <b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Collaborative Agreement</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2018, the Company entered into a research and option agreement with Astellas Pharma Inc. ("Astellas") to develop ARCs using the Company's AWE Technology Platform. Under this collaboration, the Company will utilize its AWE Platform to conjugate and label selected Astellas targeting agents with an Actinium-225 payload. The Company is also responsible for conducting preclinical validation studies on any ARCs generated. Payments from Astellas under this agreement are accounted for as a reduction to research and development expense.</p>
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4 - Equity </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2018, the Company entered into the Amended and Restated At Market Issuance Sales Agreement with B. Riley FBR, Inc. and JonesTrading Institutional Services LLC (the "ATM Sales Agreement"), pursuant to which the Company conducted its at-the market program. During the three months ended March 31, 2020, the Company sold 9.3 million common shares through its at-the-market program, resulting in net proceeds of $2.5 million. During the three months ended March 31, 2019, the Company sold 0.9 million common shares through its at-the-market program, resulting in net proceeds of $0.4 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2018, the Company and Lincoln Park Capital Fund, LLC ("Lincoln Park") entered into a purchase agreement (the "Lincoln Park Agreement") and a registration rights agreement, pursuant to which the Company has the right to sell to Lincoln Park shares of the Company's common stock having an aggregate value of up to $32.5 million, subject to certain limitations and conditions set forth in the agreement. During the three months ended March 31, 2020, the Company elected to sell to Lincoln Park 0.8 million shares and received $0.2 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the three months ended March 2019, holders of March 2018 series A warrants exercised 2.5 million shares, resulting in the Company receiving $1.5 million. The remaining March 2018 series A warrants expired in March 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Authorization for Reverse Stock Split </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Company's Annual Meeting of Stockholders held on December 18, 2019, its stockholders approved an amendment to the Company's certificate of incorporation to effect a reverse stock split of its outstanding common stock by combining outstanding shares of common stock into a lesser number of outstanding shares of common stock by a ratio of not more than 1-for-75 prior to December 18, 2020, with the exact ratio to be set within this range by the Company's Board of Directors, or Board, at its sole discretion. The Board may alternatively elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion. For more information on the potential reverse stock split, please see Note 1—Description of Business and Summary of Significant Accounting Policies herein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock Options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary of stock option activity for the three months ended March 31, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Term <br /> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br /> Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11,385</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.17</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.88</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">          -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(324</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">0.55</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Outstanding, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11,061</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">1.19</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">7.77</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Exercisable, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,278</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">6.61</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended March 31, 2020, options to purchase 0.3 million shares were cancelled upon the termination of employment for several employees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at March 31, 2020 was $1.7 million related to unvested options, which is expected to be expensed over a weighted average of 3.0 years. During the three months ended March 31, 2020 and 2019, the Company recorded compensation expense related to stock options of $0.4 million and $0.3 million, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of warrant activity for the three months ended March 31, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Term <br /> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br /> Intrinsic <br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">86,141</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.69</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.95</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">301</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Cancelled/Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">86,141</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.69</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.70</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">267</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Exercisable, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">85,934</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.68</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">2.70</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">267</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Subsequent Events</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2020, the Company sold 171 thousand shares of common stock through its at-the-market program and realized net proceeds of $35 thousand.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 24, 2020, the Company issued and sold 128.3 million shares of common stock and 82.5 million pre-funded warrants to purchase shares of common stock. The price to the public in this offering for each share of common stock was $0.15 and for each pre-funded warrant was $0.1499. Each pre-funded warrant has an exercise price of $0.0001 per share and is exercisable immediately upon issuance. The warrants are subject to certain limitations on beneficial ownership. Gross proceeds from this offering to Actinium were $31.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Net proceeds from this offering were $29.1 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2020, holders of 36.0 million pre-funded warrants exercised their warrants at $0.0001 per share and received 36.0 million shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2020, the Company issued 157 thousand shares of restricted common stock for consulting services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 19, 2020, the Company issued and sold 55.7 million shares of common stock and 21.3 million pre-funded warrants to purchase shares of common stock. The price to the public in this offering for each share of common stock was $0.325 and for each pre-funded warrant was $0.3249. Each pre-funded warrant has an exercise price of $0.0001 per share and is exercisable immediately upon issuance. The warrants are subject to certain limitations on beneficial ownership. Gross proceeds from this offering to Actinium were $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Net proceeds from this offering were $22.8 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the Company's June 2020 public offering, the Company suspended, and during the duration of the June 2020 public offering did not offer, any securities pursuant to the Lincoln Park Agreement and the ATM Sales Agreement. The Company will not make any sales of securities pursuant to the Lincoln Park Agreement and the ATM Sales Agreement unless and until a new prospectus supplement is filed with the SEC; however, the Lincoln Park Agreement and the ATM Sales Agreement remain in full force and effect.</p>
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<atnm:NatureOfBusinessPolicyTextBlock contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business -</b> Actinium Pharmaceuticals, Inc. (the "Company", "Actinium", or "We") is a clinical-stage, biopharmaceutical company applying its proprietary platform technology and deep understanding of radioimmunobiology to the development of novel targeted therapies known as ARCs or Antibody Radiation-Conjugates. Radiation is an effective therapeutic modality that is used in the treatment of over fifty percent of all cancer patients and often combined with chemotherapy and immunotherapy for greater therapeutic effect. Radiation is typically administered from outside the body, which constrains the amount that can be administered to patients due to dose-limiting toxicities. In addition, due to the diffuse nature of the external radiation beam, its usage is limited to solid tumors and cannot be used in blood cancers, which are diffuse. ARCs combine the cell-killing ability of a radioisotope payload with a targeting agent, such as a monoclonal antibody, or mAb, to deliver radiation inside the body to specific cells, to potentially generate greater efficacy and less toxicity. ARCs usage is broader than external delivered radiation as they can be used for both solid tumors and blood cancers. Blood or hematologic cancers are highly sensitive to radiation and our clinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologic cancers. Our clinical programs are focused on two primary areas: targeted conditioning prior to a cell or gene therapy procedure and therapeutics, either in combination with other agents or as a monotherapy. Our product development strategy is actively informed by clinical data with our ARCs in over 500 patients, including the ongoing SIERRA trial. Our clinical pipeline has emanated from our AWE, or Antibody Warhead Enabling technology platform, which is protected by over 110 issued and pending patents, trade secrets and know-how and is being utilized in a collaborative research partnership with Astellas Pharma, Inc.</p>
</atnm:NatureOfBusinessPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation -</b> The consolidated financial statements include the Company's accounts and those of the Company's wholly owned subsidiary.</p>
</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates in Financial Statement Presentation</b> - The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
</us-gaap:UseOfEstimates>
<atnm:PandemicOnFinancialStatements contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Impact of COVID–19 Pandemic on Financial Statements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, a novel strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China to other countries has resulted in the World Health Organization ("WHO") declaring the outbreak of COVID-19 as a "pandemic," or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world have imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses, and many local jurisdictions continue to have such restrictions in place.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As local jurisdictions continue to put restrictions in place, the Company's ability to continue to operate its business may also be limited. Such events may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could materially affect the Company's business, financial condition and results of operations. In response to COVID-19, the Company implemented remote working and thus far, has not experienced a significant disruption or delay in its operations as it relates to the clinical development or drug production of our drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The spread of COVID-19, which has caused a broad impact globally, may materially affect the Company economically. While the ultimate economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic has resulted significant disruptions in the general commercial activity and the global economy and caused financial market volatility and uncertainty in significant and unforeseen ways in the recent months. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on the Company's ability to access capital, which could in the future negatively affect the Company's liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect the Company's business and the value of the Company's common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, COVID-19 may also result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with IRB's or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, COVID-19 has not had a financial impact on the Company. However, COVID-19 has caused severe disruptions in transportation and limited access to the Company's facility, resulting in limited support from its staff and professional advisors. The small size of the Company's accounting staff and the additional responsibilities emanating from COVID-19 have presented difficulties to the Company's ability to complete this Report on Form 10-Q in a timely manner, resulting in its delay.</p>
</atnm:PandemicOnFinancialStatements>
<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary of cash, cash equivalents and restricted cash at March 31, 2020 and December 31, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><b>(in thousands)</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,942</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,254</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Restricted cash – current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash – long-term</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">391</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">391</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,381</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,693</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Current restricted cash relates to credit card accounts, while long-term restricted cash relates to a certificate of deposit held as collateral for a letter of credit issued in connection with the Company’s lease for corporate office space.</p>
</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share</b> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the reporting period. For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and warrants using the treasury stock method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three months ended March 31, 2020 and 2019, the Company's potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11,061</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7,784</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">86,141</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,473</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">97,202</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">51,257</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>
</us-gaap:EarningsPerSharePolicyTextBlock>
<atnm:AccountingPronouncementsRecentlyAdopted contextRef="From2020-01-01to2020-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Accounting Standards Recently Adopted </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, FASB issued ASU 2018-13, <i>Fair Value Measurement - Disclosure Framework (Topic 820).</i> The updated guidance improves the disclosure requirements on fair value measurements, primarily associated with Level 3 fair value measurements and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance of the standard for disclosures modified or removed with a delay of adoption of the additional disclosures until their effective date. The Company adopted this standard effective January 1, 2020 and the standard did not have a significant impact to the Company's financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2018, FASB issued ASU 2018-18, C<i>ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, </i>which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company adopted this standard effective January 1, 2020 and the standard did not have a significant impact to the Company's financial statements.</p>
</atnm:AccountingPronouncementsRecentlyAdopted>
<dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-06-29" unitRef="shares" decimals="INF"> 395154726 </dei:EntityCommonStockSharesOutstanding>
</xbrli:xbrl>

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/07/20  Actinium Pharmaceuticals, Inc.    S-3                    4:702K                                   EdgarAgents LLC/FA
↑Top
Filing Submission 0001213900-20-016168   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sun., Apr. 28, 8:57:01.1pm ET